Tuhura Biosciences, INC./NV (HURA) — 8-K Filings

All 8-K filings from Tuhura Biosciences, INC./NV. Browse 40 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (40)

TuHURA Biosciences Files 8-K: Material Agreement & Financial Obligation — Apr 22, 2026 Risk: medium
TuHURA Biosciences, Inc./NV filed an 8-K on April 22, 2026, reporting the entry into a material definitive agreement and the creation of a direct financial obli
TuHURA Biosciences Files 8-K: Officer Changes & Other Events — Apr 8, 2026 Risk: medium
TuHURA Biosciences, Inc./NV filed an 8-K on April 8, 2026, reporting on the departure of a director or officer, other events, and financial statements/exhibits.
TuHURA Biosciences Files 8-K on Financials — Apr 1, 2026 Risk: low
TuHURA Biosciences, Inc./NV filed an 8-K on April 1, 2026, reporting results of operations and financial condition. The filing includes financial statements and
TuHURA Biosciences Files 8-K — Dec 10, 2025 Risk: medium
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K on December 10, 2025, reporting the entry into a material definitive agreement and o
TuHURA Biosciences Enters Material Definitive Agreement — Dec 5, 2025 Risk: medium
On December 2, 2025, TuHURA Biosciences, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known
TuHURA Biosciences Files 8-K — Nov 25, 2025 Risk: low
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K on November 25, 2025, reporting a Regulation FD Disclosure. The company, incorporate
TuHURA Biosciences Files 8-K — Nov 18, 2025 Risk: low
TuHURA Biosciences, Inc. filed an 8-K on November 18, 2025, reporting other events and financial statements. The company, formerly known as Kintara Therapeutics
TuHURA Biosciences Files 8-K on Financials — Nov 14, 2025 Risk: low
TuHURA Biosciences, Inc. filed an 8-K on November 14, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and
TuHURA Biosciences Files 8-K for Material Agreement — Nov 4, 2025 Risk: medium
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K on November 4, 2025, reporting a material definitive agreement entered into on Novem
8-K Filing — Nov 3, 2025
TuHURA Biosciences Enters Material Definitive Agreement — Oct 31, 2025 Risk: medium
TuHURA Biosciences, Inc. announced on October 27, 2025, that it entered into a material definitive agreement. This filing also indicates the creation of a direc
TuHURA Biosciences Files 8-K for Material Agreement — Sep 11, 2025 Risk: medium
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K on September 11, 2025, reporting a material definitive agreement entered into on Sep
TuHURA Biosciences Completes Asset Acquisition/Disposition — Jun 30, 2025 Risk: medium
On June 30, 2025, TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K report detailing the completion of an acquisition or disposition o
TuHURA Biosciences Files 8-K with Corporate Updates — Jun 27, 2025 Risk: low
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K on June 27, 2025, reporting events as of June 23, 2025. The filing indicates amendme
TuHURA Biosciences Files 8-K: Shareholder Vote, Reg FD, Exhibits — Jun 24, 2025 Risk: medium
TuHURA Biosciences, Inc. filed an 8-K on June 24, 2025, reporting events as of June 23, 2025. The filing indicates a submission of matters to a vote of security
TuHURA Biosciences Files 8-K — Jun 12, 2025 Risk: low
TuHURA Biosciences, Inc. filed an 8-K on June 12, 2025, reporting events as of June 6, 2025. The filing primarily concerns financial statements and exhibits, wi
TuHURA Biosciences Files 8-K: Material Agreement & Equity Sales — Jun 6, 2025 Risk: medium
TuHURA Biosciences, Inc. announced on June 2, 2025, that it entered into a Material Definitive Agreement. The company also disclosed unregistered sales of equit
TuHURA Biosciences Files 8-K on Operations — Apr 1, 2025 Risk: low
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K on April 1, 2025, reporting on its results of operations and financial condition. Th
TuHURA Biosciences Files 8-K — Mar 18, 2025 Risk: low
TuHURA Biosciences, Inc. filed an 8-K on March 18, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
TuHURA Biosciences Files 8-K: Board & Compensation Changes — Mar 12, 2025 Risk: medium
TuHURA Biosciences, Inc. announced on March 7, 2025, a change in its board of directors and executive compensation arrangements. The filing also includes inform
TuHURA Biosciences Enters Material Definitive Agreement — Feb 14, 2025 Risk: medium
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) announced on February 12, 2025, that it entered into a Material Definitive Agreement. The company
TuHURA Biosciences Changes Auditors — Jan 3, 2025 Risk: low
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) announced on December 27, 2024, a change in its certifying accountant. The company has dismissed
TuHURA Biosciences Enters Material Definitive Agreement — Dec 12, 2024 Risk: medium
TuHURA Biosciences, Inc. announced on December 11, 2024, that it entered into a Material Definitive Agreement. The company, formerly known as Kintara Therapeuti
TuHURA Biosciences Files 8-K — Nov 25, 2024 Risk: low
TuHURA Biosciences, Inc. filed an 8-K on November 25, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly kn
TuHURA Biosciences Reports Board Changes and Compensation Updates — Nov 15, 2024 Risk: medium
TuHURA Biosciences, Inc. announced on November 12, 2024, a change in its board of directors. Specifically, the company reported the departure of directors and t
Kintara Therapeutics Reports Material Definitive Agreement & Acquisition — Oct 21, 2024 Risk: high
Kintara Therapeutics, Inc. filed an 8-K on October 21, 2024, reporting several material events as of October 18, 2024. These include entering into a material de
Kintara Therapeutics Files 8-K — Oct 15, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on October 15, 2024, reporting on events that occurred on October 14, 2024. The filing includes information related to R
Kintara Therapeutics Files 8-K — Oct 8, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on October 8, 2024, reporting on results of operations, financial condition, and Regulation FD disclosures. The filing a
Kintara Therapeutics Files 8-K on Security Holder Vote — Oct 4, 2024 Risk: medium
Kintara Therapeutics, Inc. filed an 8-K on October 4, 2024, to report on the submission of matters to a vote of its security holders. The filing does not provid
Kintara Therapeutics Files 8-K for Material Agreement — Sep 25, 2024 Risk: medium
Kintara Therapeutics, Inc. filed an 8-K on September 25, 2024, reporting the entry into a material definitive agreement. The filing also includes financial stat
Kintara Therapeutics Files 8-K — Sep 24, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on September 24, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, forme
Kintara Therapeutics Files 8-K with Shareholder Vote and Financial Updates — Sep 20, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on September 20, 2024, reporting on the submission of matters to a vote of security holders, Regulation FD disclosures,
Kintara Therapeutics Files 8-K — Sep 19, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on September 18, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not c
Kintara Therapeutics Files 8-K — Sep 18, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on September 18, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not c
Kintara Therapeutics Files 8-K — Sep 11, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on September 11, 2024, reporting on various events. The filing includes information related to financial statements and
Kintara Therapeutics Files 8-K — Sep 9, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on September 9, 2024, to report on Regulation FD disclosures and financial statements. The company, formerly known as De
Kintara Therapeutics Files 8-K — Sep 3, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on September 3, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly
Kintara Therapeutics Files 8-K — Aug 19, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on August 19, 2024, reporting on other events and financial statements. The company, formerly known as DelMar Pharmaceut
Kintara Therapeutics Files 8-K — Jul 12, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on July 12, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company,
Kintara Therapeutics to be Acquired by DelMar Pharmaceuticals — Jul 8, 2024 Risk: medium
Kintara Therapeutics, Inc. announced on July 3, 2024, that it has entered into a definitive agreement to be acquired by DelMar Pharmaceuticals, Inc. The transac

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX